Stock Market Reviews

XLO (Xilio Therapeutics, Inc.) News

Get the latest news, insights, and market updates on XLO (Xilio Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
  Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showin
  Nov 13, 2025 - $XLO
• BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
  BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025 - $XLO
• Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
  40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechn
  Nov 7, 2025 - $XLO
• Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
  Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, sho
  Nov 7, 2025 - $XLO
• Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company granted a non-qualified stock option to purchase 5,700 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of
  Nov 3, 2025 - $XLO
• Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
  WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a late-breaking poster presentation for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 5-9, 2025 in National Harbor, Maryland.
  Oct 30, 2025 - $XLO
• Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
  WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland. Xilio plans to present clinical data
  Oct 3, 2025 - $XLO
• Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
  Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2
  Sep 9, 2025 - $XLO
• Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)
  Xilio Therapeutics ( NASDAQ:XLO ) Second Quarter 2025 Results Key Financial Results Revenue: US$8.08m (up 243% from 2Q...
  Aug 16, 2025 - $XLO
• Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
  Xilio Therapeutics (XLO) delivered earnings and revenue surprises of -100.00% and -10.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 14, 2025 - $XLO